Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-09-13
Dahl Andrew M. Files Edwards Lifesciences (EW) Form 4 - September 13, 2026
Dahl Andrew M. sold 253 EW shares worth $21.3K in this Form 4 filing, reported to the SEC on 2026-09-13.
- Insider
- Dahl Andrew M.
- Issuer
- Edwards Lifesciences Corporation EW · NYSE
- Filed
- Period
- 2026-09-13
- Accession
- 0001225208-26-007811
- Source
- Official filing on sec.gov ↗
Transactions (1)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Dahl Andrew M. | 2026-09-13 | Sell | 253 | $84.37 | $21.3K | Direct |
| Net change | −253 | −$21.3K | ||||
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves. Its portfolio supports minimally invasive procedures designed for patients with advanced cardiovascular conditions, while its monitoring technologies help clinicians assess heart function and fluid status in surgical and intensive care settings. The company serves hospitals, heart centers, and healthcare professionals across major international markets, with products distributed in the United States, Europe, Japan, and other regions. Headquartered in Irvine, California, and founded in 1958, Edwards Lifesciences is recognized for its role in advancing specialized therapies for complex heart disease.
Track EW insider activity
Get alerted when Edwards Lifesciences Corporation executives buy or sell their shares.